- Home
- ATAI vs INSE Comparison
ATAI vs INSE Comparison
Compare ATAI & INSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- INSE
- Stock Information
- Founded
- ATAI 2018
- INSE 2002
- Country
- ATAI Germany
- INSE United States
- Employees
- ATAI N/A
- INSE N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- INSE Computer Software: Prepackaged Software
- Sector
- ATAI Health Care
- INSE Technology
- Exchange
- ATAI Nasdaq
- INSE Nasdaq
- Market Cap
- ATAI 282.6M
- INSE N/A
- IPO Year
- ATAI 2021
- INSE N/A
- Fundamental
- Price
- ATAI $1.41
- INSE $7.80
- Analyst Decision
- ATAI Strong Buy
- INSE Buy
- Analyst Count
- ATAI 3
- INSE 5
- Target Price
- ATAI $10.50
- INSE $12.40
- AVG Volume (30 Days)
- ATAI 1.4M
- INSE 105.2K
- Earning Date
- ATAI 05-19-2025
- INSE 05-08-2025
- Dividend Yield
- ATAI N/A
- INSE N/A
- EPS Growth
- ATAI N/A
- INSE 2060.63
- EPS
- ATAI N/A
- INSE 2.42
- Revenue
- ATAI $308,000.00
- INSE $295,200,000.00
- Revenue This Year
- ATAI $65.58
- INSE $5.10
- Revenue Next Year
- ATAI N/A
- INSE $3.52
- P/E Ratio
- ATAI N/A
- INSE $3.08
- Revenue Growth
- ATAI N/A
- INSE N/A
- 52 Week Low
- ATAI $1.03
- INSE $6.51
- 52 Week High
- ATAI $2.57
- INSE $11.61
- Technical
- Relative Strength Index (RSI)
- ATAI 44.57
- INSE 51.25
- Support Level
- ATAI $1.36
- INSE $7.32
- Resistance Level
- ATAI $1.54
- INSE $7.82
- Average True Range (ATR)
- ATAI 0.09
- INSE 0.48
- MACD
- ATAI -0.00
- INSE 0.09
- Stochastic Oscillator
- ATAI 0.00
- INSE 53.62
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.